Methylenetetrahydrofolate reductase polymorphism interacts with riboflavin intake to influence bone mineral density.
Macdonald
H M
HM
Department of Medicine and Therapeutics, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK. h.macdonald@abdn.ac.uk
McGuigan
F E
FE
Fraser
W D
WD
New
S A
SA
Ralston
S H
SH
Reid
D M
DM
D015415:Biomarkers; D015519:Bone Density / Q000187:drug effects* / Q000235:genetics / Q000502:physiology; D005260:Female; D005500:Follow-Up Studies; D005838:Genotype; D006710:Homocysteine / Q000378:metabolism; D006801:Humans; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics* / Q000378:metabolism; D008875:Middle Aged; D011110:Polymorphism, Genetic / Q000235:genetics*; D012256:Riboflavin / Q000008:administration & dosage* / Q000494:pharmacology*
D015415:Biomarkers; D006710:Homocysteine; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D012256:Riboflavin